Copyright
©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Sep 14, 2019; 25(34): 5197-5209
Published online Sep 14, 2019. doi: 10.3748/wjg.v25.i34.5197
Published online Sep 14, 2019. doi: 10.3748/wjg.v25.i34.5197
Analysis of 72 patients with colorectal high-grade neuroendocrine neoplasms from three Chinese hospitals
Zhi-Jie Wang, Man-Dula Bao, Jia-Nan Chen, Shi-Wen Mei, Hai-Yu Shen, Yun-Bin Ma, Fu-Qiang Zhao, Fang-Ze Wei, Qian Liu, Department of Colorectal Surgery, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Ke An, Department of General Surgery, China-Japan Friendship Hospital, Beijing 100029, China
Rui Li, Department of General Surgery, Beijing Hospital, Beijing 100730, China
Wei Shen, Department of Orthopedics, Lanzhou University Second Hospital, Lanzhou 730030, China
Jin-Hua Tao, Department of Colorectal Surgery, University of Chinese Academy of Sciences Zhejiang Cancer Hospital, Hangzhou 310022, China
Author contributions: Wang ZJ and Tao JH designed the research; An K, Li R, Shen W, Bao MDL, Ma YB, and Wei FZ collected the data; Chen JN, Mei SW, Shen HY, and Zhao FQ analyzed the data; Wang ZJ drafted the article; Liu Q revised the paper.
Supported by the Medicine and Health Technology Innovation Project of Chinese Academy of Medical Sciences , No. 2017-12M-1-006 .
Institutional review board statement: Our investigation received approval from the ethics committee of the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College.
Informed consent statement: All patients signed an informed consent form before the study.
Conflict-of-interest statement: The authors declare that there is no conflict of interest in regard to this research.
Data sharing statement: No additional data are available.
STROBE statement: The authors have carefully read the STROBE statement checklist of items and prepared the manuscript based on the requirements of the STROBE statement checklist of items.
Open-Access: This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Qian Liu, MD, Chief Doctor, Professor, Surgeon, Teacher, Department of Colorectal Surgery, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17, Panjiayuan Nanli, Chaoyang District, Beijing 100021, China. fcwpumch@163.com
Telephone: +86-10-87787110 Fax: +86-10-87787110
Received: July 1, 2019
Peer-review started: July 1, 2019
First decision: August 2, 2019
Revised: August 12, 2019
Accepted: August 19, 2019
Article in press: August 19, 2019
Published online: September 14, 2019
Peer-review started: July 1, 2019
First decision: August 2, 2019
Revised: August 12, 2019
Accepted: August 19, 2019
Article in press: August 19, 2019
Published online: September 14, 2019
Core Tip
Core tip: Colorectal high-grade neuroendocrine neoplasms (HGNENs) are aggressive malignancies with an extremely low incidence. Many issues, such as their classification and therapy strategies, have been controversial for a long time. We conducted this study to delineate their clinicopathologic features and clinical outcomes. There is a trend to categorize colorectal HGNENs with good morphological differentiation as a subgroup different from high-grade neuroendocrine carcinomas in the newest World Health Organization classification. We introduced this classification into our study and compared the prognoses of different subgroups.